Who owns what AI helps create?
AI now contributes to R&D across Swiss pharma, construction and industry, yet every IP right still needs a human behind it. Has your governance caught up?
3-minute read
AI is now embedded in R&D across Switzerland's pharma, construction and industrial sectors, everywhere in research, development and creative workflows. Every innovation team should be asking: if AI contributes to a creation, who owns it?
A human must sit behind every IP right
Under current IP law, the answer is clear: a human must sit behind every IP right.
- Patents must name a human researcher as inventor.
- Copyright protects only human creativity.
- Designs require a human designer.
- Trademarks are granted to an individual or a company, but never to a system.
A machine cannot own IP rights. But tools, including AI, may assist the human creator.
The landscape is moving
WIPO has launched the AI Infrastructure Interchange, a neutral platform where creators, rights-holders and developers explore practical solutions.
The EPO's Guidelines for Examination confirm that an inventive step requires a non-obvious technical solution to a technical problem, whether it is AI-assisted or not (Part G, Chapter 7).
The Swiss Federal Administrative Court confirmed in 2025 that only natural persons can be listed as inventors (B-2532/2024, 4 July 2025), but it clarified that a person who makes the relevant inventive contribution can be named as inventor even in an AI-assisted process.
What good practice looks like today
Leading AI-health companies, for example, combine patents, trade secrets, copyright and strategic licensing rather than relying on any single instrument, as the ITU-WHO-WIPO publication AI-enabled Health Innovation and IP: From idea to impact describes. They adjust the mix as they move from ideation through validation, approval, deployment and scale-up.
As Alain Labrique, Director in WHO's Department for Data, Digital Health, Analytics and AI, puts it: "The real challenge is not whether AI can generate new ideas for health, but whether those ideas can become safe, trusted and widely accessible solutions."
Where this leaves leaders
The takeaway for both legal and IT leaders: your innovation processes are already evolving internally. The question is whether your governance has caught up.
How is your organisation addressing AI-generated IP, and does your board know?
Frequently asked questions
Can an AI system be named as an inventor on a Swiss patent?
No. In judgment B-2532/2024 of 4 July 2025, the Swiss Federal Administrative Court confirmed that only natural persons can be listed as inventors.
Who can be named as inventor when AI assisted the invention?
A person who makes the relevant inventive contribution can be named as inventor, even in an AI-assisted process, according to the Swiss Federal Administrative Court.
Can AI own copyright, a design or a trademark?
No. Copyright protects only human creativity, designs require a human designer, and trademarks are granted to an individual or a company, never to a system.
How do leading AI-health companies protect their innovations?
They combine patents, trade secrets, copyright and strategic licensing rather than relying on any single instrument, and adjust the mix from ideation through validation, approval, deployment and scale-up.
Sources
WIPO, AI Infrastructure Interchange
European Patent Office, Guidelines for Examination, Part G, Chapter VII
Swiss Federal Administrative Court, press release on judgment B-2532/2024, 4 July 2025
ITU, WHO and WIPO, AI-enabled Health Innovation and IP: From idea to impact, July 2026
ITU, Intellectual property strategies for AI-enabled health innovation, 9 July 2026
Turn this insight into action.
Book a 30-minute conversation with StratEdge to explore what this means for your Board, executive team or organisation.
Book a meetingCopyright and AI: how much protection lies in AI-generated works?
Swiss copyright protects only human-created works. When does an AI-assisted work qualify, and what should your organisation put in place now?
[ ART_01 ]B2A's first casualty is the brand nobody sees
A customer asks an AI agent which product to buy. Five brands make the shortlist. The rest don't appear — without ever knowing they were competing. For CMOs, CCOs and CxOs, the rules of commercial strategy just changed.
[ ART_02 ]AI-ready? Prove it.
Two different studies. The same blind spot. Companies are measuring AI readiness through employee training and adoption rates, while underestimating leadership's own responsibility to make the organisation AI-ready.
[ ART_04 ]